Cambridge Cognition (LSE:COG) has opened its Winterlight speech assessment to academic researchers, it announced on 12 November 2026. Until now, academics could only use the technology through bespoke collaborations. The digital health company now offers it through its CANTAB Connect platform. A holdings notification followed on 11 November. Both come after interim results in September that showed Revenue growth and a narrower loss.
What the company does
Cambridge Cognition develops digital tools that measure brain health and cognitive function. Its best-known product is CANTAB, a set of computerised cognitive tests used in pharmaceutical Clinical Trials and in academic research. According to the company, CANTAB has been used in more than 3,700 publications and more than 600 clinical trials. Winterlight analyses speech to assess cognition. Customers include drug developers, researchers and, increasingly, healthcare and consumer wellness organisations.
Latest developments
The company said the Winterlight launch is meant to support independent validation of the tool, which could help it gain wider use in Drug Development and healthcare. The announcement cited an academic study of 266 participants showing the assessment's ability to discriminate between groups. It also referred to an automatic speech recognition project started earlier this year to strengthen the speech offering. No pricing was disclosed.
There has also been Partnership news. On 21 September the company announced a partnership with C2N and The Alzheimer's Trust, and on 6 October it said it had joined an NHS study led by Imperial College. On 23 September directors and senior managers announced share purchases.
Financial picture
In its interim results for the six months to 30 June 2026, published on 16 September, revenue rose 16% to £5.0m. This included £0.1m from new healthcare and consumer wellness pilots. New sales orders were £6.0m, and the order book stood at £16.1m. The adjusted EBITDA loss narrowed to £0.3m and Operating Cash Flow was positive. Cash at the period end was £0.6m, and the company said it was debt-free after repaying its borrowings.
Since the period end, the company completed a fundraising of about £2.6m in July 2026, after a placing and retail offer announced in June and approved at a general meeting on 10 July. It said the money would support Investment for future growth. It expects full-year revenue of at least £10.0m, even though £0.7m of contracted revenue has been rescheduled.
Sector and index context
Demand for digital cognitive assessment is closely linked to neuroscience trial activity, especially in Alzheimer's disease, where new treatments have increased interest in early detection and monitoring. Biotech funding conditions affect how many trials start. Within the FTSE AIM All Share Index, Cambridge Cognition (LSE:COG) is a small healthcare technology company, and its shares can move sharply on contract news.
Key risks
Revenue can be uneven because it depends on when clinical trials start, and customers can delay or reschedule work, as the £0.7m of rescheduled revenue shows. Cash at the half-year was modest, so the company relies on keeping operating cash flow positive and on the July fundraising. Other risks include competition from other digital biomarker providers and the challenge of building revenue in new markets such as academia and healthcare.
What to watch next
Investors will watch whether the company reaches its target of at least £10.0m in full-year revenue and how far the order book grows. They will also look for take-up of Winterlight among academic users, progress in the C2N partnership and the Imperial-led NHS study, and early revenue from the healthcare and consumer wellness pilots.






Please wait processing your request...